Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ME 344

Next Previous
X
Search
Drug Profile

ME 344

Alternative Names: ME-344; NV-344

Latest Information Update: 16 May 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novogen
  • Developer MEI Pharma; Sarah Cannon Research Institute; Spanish National Cancer Research Centre; Tennessee Oncology
  • Class Antineoplastics; Isoflavones; Small molecules
  • Mechanism of Action Mitochondrial oxidative phosphorylation inhibitors; MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Colorectal cancer
  • Preclinical Acute myeloid leukaemia
  • No development reported HER2 negative breast cancer
  • Discontinued Cervical cancer; Ovarian cancer; Small cell lung cancer

Most Recent Events

  • 09 May 2024 MEI Pharma anticipates to provide an update on new formulation of ME 344, in 1H of 2025
  • 11 Apr 2024 Interim adverse events and efficacy data from a phase-I trial in Colorectal cancer released by MEI Pharma
  • 08 May 2023 Phase-I clinical trials in Colorectal cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT05824559)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top